Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Ezetimibe; Fluvastatin

Criteria

Inclusion Criteria:

• Patients aged 18-75 Primary hypercholesterolemia Signed informed consent

Exclusion Criteria:

• Patients involved in clinical trials 3 months prior to inclusion Patients treated with drugs specified in protocol Fertile women not using contraceptive methods

Other protocol defined in and exclusion criteria may apply